EMA’s Medical Literature Monitoring: Shakedown or Shakeup

Posted on October 27th, 2015 by Julio dos Anjos in Pharmacovigilance

Although, quite a lot of existing flows have to change and new ones have to be implemented, there are, also, quite a lot of benefits, most of them for EMA, and some, not so obvious, for the MAH’s. Of these last ones, many are found by looking at the information, now made available by EMA, as an information professional in a pharmacovigilance context, as well as a pharmacovigilance analyst in an information rich environment.

Read more about EMA’s Medical Literature Monitoring

 

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales

Julio dos Anjos
Professional Services Consultant

Connect on LinkedIn
http://we-have-economical-free-shipping-discount.com/

Related posts

• Webinar: Using machine learning to identify adverse events from scientific literature
• Why literature is a valuable source for signal detection: From the EU point of view
• Elsevier uses machine learning to benefit pharmacovigilance
• How Big Data Transforms Reactive Drug Safety to Proactive Pharmacovigilance
• Are Drug-Drug Interactions Today’s Biggest Health Threat?